{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:39:04Z","timestamp":1787841544711,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>In 1903, Dr. John Auer first observed needle-like rods in what he initially mistook for lymphocytes from a patient with fever, coagulopathy, and splenomegaly. Later discovered in myeloblasts, these \u201cAuer rods\u201d emerged as a defining feature of myeloid malignancies. Among them, acute promyelocytic leukemia (APL), recognized as a distinct clinical entity in 1957, was once considered the most lethal acute leukemia due to its severe coagulopathy and alarmingly high early mortality rate. However, landmark breakthroughs, particularly the introduction of all-trans retinoic acid in the 1980s and arsenic trioxide in the 1990s, transformed APL into the most curable form of acute leukemia, provided that treatment begins early. This illustrated review highlights over a century since Auer rods were first identified, offering a concise, visually guided overview of APL\u2019s epidemiology, clinical presentation, and diagnostic strategies. We explore modern and practical therapeutic approaches, emphasize risk-adapted treatments, and address major complications, including differentiation syndrome, coagulopathy, and central nervous system involvement. The remarkable evolution of APL\u2014from a highly fatal disease to the most treatable leukemia\u2014highlights how our understanding of disease pathophysiology and biology can transform treatment strategies and improve patient outcomes.<\/jats:p>","DOI":"10.4103\/hemoncstem.hemoncstem-d-25-00007","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T02:00:08Z","timestamp":1745373608000},"page":"5-8","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Marking over a century of Auer rods: An illustrated review of acute promyelocytic leukemia"],"prefix":"10.4103","volume":"18","author":[{"given":"Ruah","family":"Alyamany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Alfayez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"issue":"(2)","key":"R1-20250430","first-page":"178","article-title":"Acute promyelocytic leukemia: a summary","volume":"9","author":"Ryan","year":"2018","journal-title":"J Adv Pract Oncol"},{"key":"R2-20250430","doi-asserted-by":"crossref","first-page":"1062524","DOI":"10.3389\/fonc.2022.1062524","article-title":"The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions","volume":"12","author":"Iyer","year":"2023","journal-title":"Front Oncol"},{"issue":"(4)","key":"R3-20250430","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3324\/haematol.2011.041970","article-title":"Therapy-related acute promyelocytic leukemia","volume":"96","author":"Ravandi","year":"2011","journal-title":"Haematologica"},{"issue":"(6)","key":"R4-20250430","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J Clin Oncol"},{"issue":"(1)","key":"R5-20250430","doi-asserted-by":"crossref","first-page":"e35662","DOI":"10.1002\/cncr.35662","article-title":"Long\u2010term follow\u2010up of a phase 2 study of all\u2010trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia","volume":"131","author":"Jen","year":"2025","journal-title":"Cancer"},{"issue":"(7)","key":"R6-20250430","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2011.78","article-title":"Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry","volume":"25","author":"Lehmann","year":"2011","journal-title":"Leukemia"},{"issue":"(8)","key":"R7-20250430","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2012-02-410746","article-title":"All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)","volume":"120","author":"Iland","year":"2012","journal-title":"Blood"},{"issue":"(13)","key":"R8-20250430","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"issue":"(3)","key":"R9-20250430","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.clml.2015.11.018","article-title":"Pseudotumor cerebri in acute promyelocytic leukemia patients on intergroup protocol 0129: clinical description and recommendations for new diagnostic criteria","volume":"16","author":"Coombs","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"(3)","key":"R10-20250430","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/10428194.2021.1992757","article-title":"Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline \u2018chemotherapy-free\u2019 therapy","volume":"63","author":"Ramos Perez","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"(2)","key":"R11-20250430","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"New Engl J Med"},{"key":"R12-20250430","author":"Platzbecker","year":"2024","journal-title":"First results of the APOLLO trial: a randomized phase III study to compare ATO combined with ATRA versus standard AIDA regimen for patients with newly diagnosed, high-risk acute promyelocytic leukemia"},{"issue":"(18)","key":"R13-20250430","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.32196","article-title":"Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia","volume":"125","author":"Chamoun","year":"2019","journal-title":"Cancer"},{"issue":"(23)","key":"R14-20250430","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1002\/cncr.27623","article-title":"Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975\u20132008","volume":"118","author":"Chen","year":"2012","journal-title":"Cancer"},{"issue":"(19)","key":"R15-20250430","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood.2019000962","article-title":"How I treat thrombotic thrombocytopenic purpura in pregnancy","volume":"136","author":"Ferrari","year":"2020","journal-title":"Blood"},{"issue":"(10)","key":"R16-20250430","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","article-title":"Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab","volume":"129","author":"Abaza","year":"2017","journal-title":"Blood"},{"key":"R17-20250430","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1182\/bloodadvances.2019001278","article-title":"A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535","volume":"4","author":"Lancet","year":"2020","journal-title":"Blood Adv"},{"issue":"(1)","key":"R18-20250430","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bjhh.2016.11.001","article-title":"Administration of all-trans retinoic acid through enteral tubes in acute promyelocytic leukemia: the handling of cytotoxic agents and clinical benefits","volume":"39","author":"Okumura","year":"2017","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"(18)","key":"R19-20250430","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1182\/blood-2013-10-512640","article-title":"How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia","volume":"123","author":"Sanz","year":"2014","journal-title":"Blood"},{"key":"R20-20250430","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1182\/blood-2014-04-568121","article-title":"Arsenic trioxide and mannitol for the treatment of acute promyelocytic leukemia relapse in the central nervous system","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"R21-20250430","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2023-179644","article-title":"An entirely oral regimen of oral-arsenic trioxide\/all-trans retinoic acid\/ascorbic acid in newly-diagnosed acute promyelocytic leukaemia (APL): updated results of an ongoing multicentre trial","volume":"142(Suppl 1)","author":"Gill","year":"2023","journal-title":"Blood"},{"issue":"(21)","key":"R22-20250430","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood.V118.21.83.83","article-title":"Late relapses following all-trans retinoic acid for acute promyelocytic leukemia are uncommon, respond well to salvage therapy and occur independently of prognostic factors at diagnosis: long-term follow-up of North American Intergroup Study I0129","volume":"118","author":"Douer","year":"2011","journal-title":"Blood"},{"key":"R23-20250430","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1200\/JOP.18.00328","article-title":"Associated content treatment of acute promyelocytic leukemia in adults","volume":"14","author":"Osman","year":"2018","journal-title":"JOP"},{"issue":"(1)","key":"R24-20250430","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/ejh.13872","article-title":"Auer rods and faggot cells: a review of the history, significance and mimics of two morphological curiosities of enduring relevance","volume":"110","author":"Sehgal","year":"2023","journal-title":"Eur J Haematol"},{"key":"R25-20250430","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","article-title":"Acute promyelocytic leukemia: from highly fatal to highly curable: a historical view of acute promyelocytic leukemia (APL)","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"issue":"(4)","key":"R26-20250430","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1038\/bcj.2015.25","article-title":"Acute promyelocytic leukemia: where did we start, where are we now, and the future","volume":"5","author":"Coombs","year":"2015","journal-title":"Blood Cancer J"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.hemoncstem-D-25-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:00:40Z","timestamp":1787839240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.hemoncstem-D-25-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/hemoncstem.hemoncstem-d-25-00007","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2025-02-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}